Overview

Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical research study is to learn if patients who receive vinflunine plus best supportive care live longer than patients who receive best supportive care alone. This study will also investigate patient benefit, safety and whether or not vinflunine shrinks or slows the growth of the cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Pierre Fabre Medicament

Collaborator:

Bristol-Myers Squibb

Treatments:

Vinblastine